Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Phase 2/3 × Radiotherapy × Tumor-Agnostic × Clear all

Phase

Phase 2 10 Phase NA 8 Phase 1 7 Phase 1/2 2 Phase EARLY_PHASE1 1 Phase 4 1 Phase 3 1 Phase 2/3 1

Status

Not yet recruiting 1

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 12 Lymphoid 8 Other hematologic neoplasm 7 Head & Neck 7 Thoracic 3 Sarcoma 3 CNS 3 Myeloid 2 Classical hematology 2 Tumor-Agnostic 1 Plasma cell 1 Genitourinary 1 Endocrine 1 Dermatologic 1

Conditions

Interventions

Oxaliplatin 3 cabazitaxel 2 Radiation 2 vinflunine 1 sugemalimab 1 pembrolizumab 1 osimertinib 1 nedaplatin 1 jinfukang 1 enzalutamide 1 empagliflozin 1 coenzyme Q10 1 camrelizumab 1 beta-Glucans 1 apatinib 1 abiraterone 1 Waiting Lists 1 Tyrosine Kinase Inhibitors 1 Surgical Procedures, Operative 1 Starch 1 Standard of Care 1 Sodium Chloride 1 Sevoflurane 1 Saline Solution, Hypertonic 1 Saline Solution 1 S 1 (combination) 1 Radiotherapy, Intensity-Modulated 1 Radiotherapy 1 Pemetrexed 1 Neck Dissection 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT05144100 2021-12-03

SCOPE

Tata Memorial Centre

Phase 2/3 Not yet recruiting

Carcinoma

Data powered by HemOnc (CC BY 4.0) Colophon ⚡